Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

WHATABOUTSTOCKS May. 13 at 5:58 PM

$TLSA GC be like ''tiziana cures hantavirus''

1 · Reply

Iceman89 May. 13 at 2:58 PM

$TLSA Huge buys at $1.5 just went through.

2 · Reply

Iceman89 May. 12 at 8:56 PM

$TLSA With Makary gone from the FDA, one would think that the approvals would get easier as that was one of the pain points. Could bode well for Foralumabs accelerated approval. I personally thought that Makary didn't do a bad job. https://www.fiercepharma.com/pharma/fda-commissioner-marty-makary-resigns-capping-turbulent-tenure

0 · Reply

Dogstocks12 May. 12 at 8:48 PM

$SPY $QQQ $TLSA $NVDA $BTC.X What's even worse is the Idiot Republican Senators answers when asked about Orange Idiots comment. "Would have to see it in context" It was a straight forward question with his straight forward answer! Impeach this asshole. Let him and his billionaire friends build this country without the help of the PEOPLE....

3 · Reply

Iceman89 May. 12 at 8:47 PM

$TLSA bots re-posting each others spam with the wrong Tiziana ticker 😂😂😂

0 · Reply

SPY700baby May. 12 at 8:39 PM

$BTC.X $NVDA $QQQ $SPY $TLSA that’s our retarded president Donny due nothing

2 · Reply

Dogstocks12 May. 12 at 8:37 PM

$SPY $QQQ $TLSA $NVDA $BTC.X

1 · Reply

ThinkYouCan May. 12 at 8:18 PM

$SPY $QQQ $TLSA $NVDA $BTC.X "I take no responsibility" President at it again.

1 · Reply

rp6577 May. 12 at 7:14 PM

$TLSA dips being bought up

0 · Reply

OfficialStocktwitsUser May. 12 at 2:43 PM

$TLSA RSI: 78.00, MACD: 0.0658 Vol: 0.12, MA20: 1.35, MA50: 1.31 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Tiziana Life announces publication of preclinical data in bioRxiv preprint

Apr 16, 2026, 7:00 AM EDT - 27 days ago

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Apr 14, 2026, 7:00 AM EDT - 4 weeks ago

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

Apr 1, 2026, 7:00 AM EDT - 6 weeks ago

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

2026-02-25T12:25:15.000Z - 2 months ago

Tiziana Life Sciences announces new data on nasal foralumab

Feb 25, 2026, 7:00 AM EST - 2 months ago

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

2026-01-20T16:20:10.000Z - 4 months ago

Tiziana Life Sciences announces publication of intranasal foralumab results

Jan 20, 2026, 11:15 AM EST - 4 months ago

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Jan 16, 2026, 2:45 PM EST - 4 months ago

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

2026-01-16T12:05:16.000Z - 4 months ago

Tiziana Life Sciences prices 6.4M shares at $1.25 in registered direct offering

Jan 16, 2026, 7:00 AM EST - 4 months ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Jan 9, 2026, 7:00 AM EST - 4 months ago

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

2025-12-29T13:15:44.000Z - 4 months ago

Tiziana Life Sciences files annual safety report for intranasal foralumab

Dec 29, 2025, 8:00 AM EST - 4 months ago

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

2025-12-19T16:05:39.000Z - 5 months ago

Tiziana Life Sciences Chairman raises stake to 36% with acquisition of shares

Dec 19, 2025, 11:00 AM EST - 5 months ago

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Dec 17, 2025, 10:00 AM EST - 5 months ago

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

2025-12-17T13:50:17.000Z - 5 months ago

Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s trial

Dec 17, 2025, 8:45 AM EST - 5 months ago

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

2025-12-15T20:15:08.000Z - 5 months ago

Tiziana Life Sciences CEO Ivor Elrifi purchases 163,400 shares

Dec 15, 2025, 3:07 PM EST - 5 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

2025-12-15T12:35:32.000Z - 5 months ago

Tiziana Life Sciences announces withdrawal of proposed public offering

Dec 15, 2025, 7:30 AM EST - 5 months ago

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

2025-12-12T19:15:11.000Z - 5 months ago

Tiziana Life Sciences to dose first patient in Phase 2 Alzheimer’s trial

Dec 12, 2025, 2:10 PM EST - 5 months ago

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

2025-12-02T12:05:39.000Z - 5 months ago

Tiziana Life Sciences plans to spinout IL-6 asset into separate listed company

Dec 2, 2025, 7:00 AM EST - 5 months ago

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

2025-11-25T13:40:48.000Z - 6 months ago

Tiziana Life announces Phase 2 foralumab study accepted into Healey ALS program

Nov 25, 2025, 8:30 AM EST - 6 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Nov 13, 2025, 8:30 AM EST - 6 months ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

2025-10-29T11:22:32.000Z - 7 months ago

Tiziana Life Sciences to present at BIO-Europe in Vienna

Oct 29, 2025, 7:00 AM EDT - 7 months ago

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Sep 30, 2025, 8:30 AM EDT - 8 months ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

2025-09-25T12:35:22.000Z - 8 months ago

Tiziana Life Sciences to advance TZLS-501 monoclonal antibody

2025-09-24T12:40:39.000Z - 8 months ago

Tiziana Life announces poster presentation on intranasal foralumab trial

Sep 24, 2025, 8:30 AM EDT - 8 months ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

2025-09-15T12:05:13.000Z - 8 months ago

Tiziana Life Sciences announces U.S. DoD awarded research grant to study SCI

Sep 15, 2025, 8:00 AM EDT - 8 months ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

2025-09-09T14:10:16.000Z - 8 months ago

Tiziana Life Sciences reports CEO purchased 14,848 shares

2025-09-09T12:38:23.000Z - 8 months ago

Tiziana Life Sciences announces purchase of shares by CEO

2025-09-05T12:35:13.000Z - 8 months ago

Tiziana Life Sciences announces purchase of shares by chairman

Sep 5, 2025, 8:30 AM EDT - 8 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

2025-08-14T12:41:41.000Z - 9 months ago

Tiziana Life doses first patient in Phase 2a trial of intranasal foralumab

Aug 14, 2025, 8:30 AM EDT - 9 months ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 9 months ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Jul 21, 2025, 7:00 AM EDT - 10 months ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 10:30 AM EDT - 11 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 11 months ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 1 year ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 9, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 11, 2025, 9:15 AM EST - 1 year ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Jan 23, 2025, 3:00 PM EST - 1 year ago

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Jan 23, 2025, 8:54 AM EST - 1 year ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Jan 22, 2025, 4:05 PM EST - 1 year ago

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Jan 8, 2025, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Nov 1, 2024, 1:00 PM EDT - 1 year ago

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Oct 30, 2024, 10:29 PM EDT - 1 year ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Appoints New Chief Executive Officer

WHATABOUTSTOCKS May. 13 at 5:58 PM

$TLSA GC be like ''tiziana cures hantavirus''

1 · Reply

Iceman89 May. 13 at 2:58 PM

$TLSA Huge buys at $1.5 just went through.

2 · Reply

Iceman89 May. 12 at 8:56 PM

0 · Reply

Dogstocks12 May. 12 at 8:48 PM

3 · Reply

Iceman89 May. 12 at 8:47 PM

$TLSA bots re-posting each others spam with the wrong Tiziana ticker 😂😂😂

0 · Reply

SPY700baby May. 12 at 8:39 PM

$BTC.X $NVDA $QQQ $SPY $TLSA that’s our retarded president Donny due nothing

2 · Reply

Dogstocks12 May. 12 at 8:37 PM

$SPY $QQQ $TLSA $NVDA $BTC.X

1 · Reply

ThinkYouCan May. 12 at 8:18 PM

$SPY $QQQ $TLSA $NVDA $BTC.X "I take no responsibility" President at it again.

1 · Reply

rp6577 May. 12 at 7:14 PM

$TLSA dips being bought up

0 · Reply

OfficialStocktwitsUser May. 12 at 2:43 PM

0 · Reply

Iceman89 May. 12 at 9:59 AM

$TLSA https://www.roche.com/media/releases/med-cor-2026-04-13

1 · Reply

rp6577 May. 11 at 7:34 PM

$TLSA only a couple of weeks away. Then we have the big SPMS readout hot on its tails. Largely seen as a big derisking and inflection point for the company $XBI $LABU

0 · Reply

Housatonic1864 May. 11 at 4:45 PM

$TLSA hit $1.65 for a bit🤑

0 · Reply

cubie May. 11 at 3:57 PM

$TLSA everybody a winner

1 · Reply

Gegau001 May. 11 at 2:53 PM

$TLSA Back in the green shortly! 🥳

0 · Reply

RichP0 May. 11 at 9:28 AM

$TLSA I'm no 'chartist', but doesn't all these green candles buying above the SMA20&50, and about to go over the SMA200 mean strong buy signal ready for a breakout?

1 · Reply

Thatcher123 May. 9 at 9:33 PM

$HGRAF Newbie "We make the best graphene in the world" Graphene is a "miracle" material 200X stronger than steel, lighter than aluminum and 20X more conductive than copper Hydrograph Clean Power HGRAF www.hydrograph.com Hydrograph SNYTHETIC pure graphene will produce 70% to 90% bottom line profit margins. When you attempt to compare Hydrograph’s graphene to others you realize that there is NO comparison. "We make products lighter, faster and stronger." Christopher M. Sorensen Kansas State University Inventor of HydroGraph Graphene Technology Watch Youtube https://youtu.be/oLxQI8RCXjc Is Graphene the new OIL ?? https://x.com/i/status/1957095349144764583 Hydrograph video Nuclear Scientist Kerry Landis and Newsletter writer Jay Taylor Excellent https://www.youtube.com/watch?v=ibMeHK_OCFk Jay Taylor "HydroGraph is indeed the most exciting and transformative company story I have covered over the past 40+ years that I have edited J Taylor’s Gold, Energy & Tech Stocks." $TLSA $AMZN $META $SPACEX.X

1 · Reply

Housatonic1864 May. 8 at 8:21 PM

$TLSA well, grip them reigns tighter. Monday should pass $1.65. It’s a great day to be a Tiziana Holder🫡

0 · Reply

Housatonic1864 May. 8 at 6:34 PM

$TLSA by the end of the year, I’m hoping this will surpass $BBAI

0 · Reply

Housatonic1864 May. 8 at 6:32 PM

$TLSA we’ll see what Power Hour holds! Next week if this doesn’t rest at $1.72, I’m gonna have a conniption 😂

0 · Reply

hopehelpsyou May. 8 at 5:12 PM

$TLSA Taking out the 200 ma next..... BUY BUY BUY Orphan drug designation is coming imo, they submitted that peer reviewed paper 90 days ago to support the approval. The FDA usually responds within 90 days. The FDA request of more info was sent, we'll see but judging from them already giving Fast Track designation, that means they love the science. World Parkinson Conference coming, topline data due as well. THE PERFECT STORM! VERY FACKIN

0 · Reply

Bretty_0 May. 8 at 5:04 PM

$TLSA World Parkinson Congress, taking place May 24-27....tick tock. Big news will happen when it happens. Set the story,set the tone and patience is a virtue. The journey started years ago and 2026 will be groundbreaking! Peace and much love,let's make the world a better place.

0 · Reply

Market Cap	194.71M
Revenue (ttm)	0.00
Net Income (ttm)	-18.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	251,741
Avg Vol	152,838
Day's Range	N/A - N/A
Shares Out	127.26M
Stochastic %K	79%
Beta	0.42
Analysts	Strong Sell
Price Target	$8.00